BCLI Stock Summary and Trading Ideas (Brainstorm Cell Therapeutics | NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics trades on the NASDAQ stock market under the symbol BCLI.

As of April 4, 2025, BCLI stock price declined to $1.15 with 10,353 million shares trading.

BCLI has a beta of 0.85, meaning it tends to be less sensitive to market movements. BCLI has a correlation of 0.01 to the broad based SPY ETF.

BCLI has a market cap of $6.56 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCLI traded as high as $70.50 and as low as $1.05.

The top ETF exchange traded funds that BCLI belongs to (by Net Assets): VXF.

BCLI has underperformed the market in the last year with a price return of -88.6% while the SPY ETF was flat at -0.1%. BCLI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.4% and -18.4%, respectively, while the SPY returned -14.4% and -10.4%, respectively.

BCLI support price is $1.14 and resistance is $1.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCLI shares will trade within this expected range on the day.